Results for: Life Sciences

Life sciences toolmaker Danaher (DHR) reported better-than-expected financial results for the first quarter of 2024. Despite an 18% decline in its Biotechnology division, the company’s Life Sciences and Diagnostics divisions recorded growth, resulting in a 3% overall revenue decline compared to the same period last year. The company also reported strong operating cash flow. Danaher’s competitors, such as Repligen, Bio-Rad, and Thermo Fisher Scientific, are expected to be closely watched in light of these positive results.

CustomerInsights.AI (CIAI), a provider of technology-enabled solutions for Life Sciences companies, has partnered with Ambit, a consulting firm specializing in rare and specialty diseases.

This partnership combines CIAI’s scalable data architecture, automated workflows, and AI capabilities with Ambit’s consulting expertise in rare diseases. Together, they aim to accelerate the development and deployment of data and analytics solutions for rare and specialty disease companies.